Renaissance Capital logo

TNYA News

US IPO Weekly Recap: Biotechs pop and Robinhood flops in a record 20 IPO week

ICVX

The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed, citing either volatility or market conditions: vehicle battery maker Clarios International (BTRY), specialty...read more

Heart disease biotech Tenaya Therapeutics prices upsized IPO at $15 midpoint

TNYA

Tenaya Therapeutics, a preclinical biotech developing multiple therapies to treat heart disease, raised $180 million by offering 12 million shares at $15, within the range of $14 to $16. The company offered 2 million more shares than anticipated. The company's multi-modality drug discovery platform targets both genetic and non-genetic forms of heart disease, and consists of a gene...read more

Heart disease biotech Tenaya Therapeutics sets terms for $150 million IPO

TNYA

Tenaya Therapeutics, a preclinical biotech developing multiple therapies to treat heart disease, announced terms for its IPO on Monday. The South San Francisco, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Tenaya Therapeutics would command a fully diluted market value of $585...read more

US IPO Weekly Recap: Micro-caps lead a quiet 2 IPO week

RNAZ

After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million.  Preclinical RNA biotech Transcode Therapeutics (RNAZ) priced at $4 to raise $25 million at a $54 million market cap. This oncology biotech develops RNA therapeutics for the treatment of solid...read more